Herein, we review the preclinical and clinical data supporting that BRAFi and MEKi are also immunomodulating drugs and suggest that combining targeted therapy with immunotherapy is potentially ...

BRB-002 is a novel, investigational, immunomodulating protein therapy that targets CD47 as a potential treatment option for patients with atherosclerotic cardiovascular disease (ASCVD).

BRB-002 is a novel, investigational, immunomodulating protein therapy that targets CD47 as a potential treatment option for patients with atherosclerotic cardiovascular disease (ASCVD). By targeting ...

Overcoming barriers and improving genetic testing completion rate for hereditary cancer in an underserved population at a large safety net hospital. Genomic therapy matching in rare and refractory ...

The first part of this review focuses on the potential immunomodulating properties of anti-infective agents, beginning with antibacterial and antiviral agents. After millenniums of fatal ...

And they keep myeloma from weakening the immune system. Immunomodulating agents, targeted antibodies, and Chimeric antigen receptor (CAR) T-cell therapy are all immunotherapies that can help ...

Immunomodulating nutrients added to enteral feedings given to mechanically ventilated patients in the intensive care unit (ICU) do not decrease the incidence of infection, a new study suggests.

According to the National Cancer Institute, these immunomodulating agents cause cells to release interleukin-2 (IL-2). IL-2 is a protein that increases the body’s white blood cells, such as ...